Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
GlaxoSmithKline (Thailand) Limited, commonly referred to as GSK Thailand, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Thailand. Established in 1999, GSK Thailand has made significant strides in delivering innovative healthcare solutions across the region, focusing on pharmaceuticals, vaccines, and consumer healthcare products.
With a commitment to improving health and well-being, GSK Thailand offers a diverse portfolio that includes prescription medicines, over-the-counter products, and vaccines, distinguished by their quality and efficacy. The company has achieved notable market presence, contributing to GSK's global reputation as a leader in research and development. Through its dedication to scientific advancement and community health, GSK Thailand continues to play a vital role in enhancing the quality of life for individuals across the nation.
+58 vs industry average
GlaxoSmithKline (Thailand) Limited’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for GlaxoSmithKline (Thailand) Limited yet.
GlaxoSmithKline (Thailand) Limited currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, and any relevant emissions data or climate commitments would be cascaded from its parent organisation.
GSK plc has established various climate initiatives and targets, which include commitments to reduce carbon emissions across its operations. These initiatives are part of a broader strategy to achieve sustainability and align with global climate goals. However, specific reduction targets or achievements for GlaxoSmithKline (Thailand) Limited have not been detailed.
As a subsidiary, GSK Thailand's climate commitments are influenced by the overarching goals set by GSK plc, which include participation in initiatives such as the Science Based Targets initiative (SBTi), CDP, and RE100. These commitments reflect a dedication to reducing greenhouse gas emissions and transitioning to renewable energy sources.
In summary, while GlaxoSmithKline (Thailand) Limited does not currently report specific emissions data, it is aligned with the climate commitments and reduction strategies of its parent company, GSK plc, which are aimed at fostering a sustainable future.
No climate goals have been disclosed for GlaxoSmithKline (Thailand) Limited yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more